LncRNA FAS-AS1 inhibits the progression of non-small cell lung cancer through regulating miR-19a-5p
C.-B. Yang, S.-W. Xiao, S.-M. Cheng, C. Zhang Department of Thoracic Surgery, Zhenhai People’s Hospital, The First Affiliated Hospital of Zhejiang University, Shangcheng District, Hangzhou, China. paoduhanyuan19997@126.com
OBJECTIVE: Non-small cell lung cancer (NSCLC) is one of the most common and deadly tumors in the world. LncRNA FAS-AS1 was abnormally expressed in various cancers, such as non-small cell lung cancer. However, the underlying mechanism of FAS-AS1 in NSCLC remains to be elucidated.
MATERIALS AND METHODS: The levels of FAS-AS1 and miR-19a-5p were measured using qRT-PCR in NSCLC cells. MTT and cell colony formation assays were performed to detect cell proliferative capacity. Transwell assay was carried out to measure cell migration and invasion. The relationship between FAS-AS1 and miR-19a-5p was confirmed using Luciferase reporter assay. Xenograft tumor experiment was conducted to detect the tumor growth in vivo.
RESULTS: FAS-AS1 was remarkably down-regulated in NSCLC cells. FAS-AS1 inhibited cell proliferation, migration, and invasion in NSCLC cells. Additionally, FAS-AS1 directly targeted miR-19a-5p and negatively regulated the expression of miR-19a-5p in NSCLC cells. Furthermore, FAS-AS1 overexpression restored the promotion of miR-19a-5p overexpression on proliferation, migration, and invasion of NSCLC cells. Additionally, suppression of FAS-AS1 abrogated the inhibitory effects of miR-19a-5p knockdown on the progression of NSCLC. FAS-AS1 suppressed the tumor growth in vivo.
CONCLUSIONS: FAS-AS1 suppressed cell proliferation, migration, and invasion by sponging miR-19a-5p in NSCLC, indicating that FAS-AS1 might be a potential biomarker and therapeutic target for NSCLC.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
C.-B. Yang, S.-W. Xiao, S.-M. Cheng, C. Zhang
LncRNA FAS-AS1 inhibits the progression of non-small cell lung cancer through regulating miR-19a-5p
Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 7
Pages: 3775-3785
DOI: 10.26355/eurrev_202004_20842